Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
Faiq I Gorial, Mohammed Fauzi Maulood, Ahmed S Abdulamir, Ahmed Sameer Alnuaimi, Manal K Abdulrrazaq, Fadil Agla Bonyan
Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interest statement None.
Trial registry number
References
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med
Da, Roura-Piloto, Moral-Escudero, Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID), Int J Gen Med,
doi:10.2147/IJGM.S329810Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients J o u r n a l P r e -p r o o f hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Faigenbaum, June, Cytokine storm, N Engl J Med
Horby, Landrain, Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
Jackman, Rhoads, Cornwell, Kandarian, Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway, Exp Cell Res
Laujwy, Rosin, Agha, The CONSORT (CONsolidated standards of reporting trials) 2010 guideline, Int. J. Surg
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial RMD Open,
doi:10.1136/rmdopen-2020-001455Nieto-Torres, Verdiá-Báguena, Jimenez-Guardeno, Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome, Virology
Reyes, Hu, Teperman, Anti-inflammatory therapy for COVID19 infection: the case for colchicine, Ann Rheum Dis
Richter, Boldescu, Graf, Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-activated prodrugs as antiviral agents, ChemMedChem
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients; a clinical trial
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Can J Infect Dis Med Microbiol
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Vrachatis, Giannopoulos, Giotaki, Impact of colchicine on mortality in patients with COVID-19. A metaanalysis, Hellenic J Cardiol
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med. Published online,
doi:10.1001/jamainternmed.2020.0994Yu, Du, Ojcius, Measures for diagnosing and treating infections bya novel coronavirus responsible for a pneumonia outbreak originating in Wuhan
